ERBB2 and breast carcinoma: In the adjuvant setting trastuzumab, a monoclonal antibody against Her2 (an EGFR receptor overexpressed in approximately 20% of breast cancers), has improved the overall survival in women with breast cancers overexpressing Her2, by 5–10% at 5 years (Slamon et al., 2011).